With biosimilar drug development on the rise, researchers explore efficacy

A new article focuses on the first biosimilar monoclonal antibody to be approved in Europe. "While there is growing interest in biosimilars and their potential to reduce the cost of treatment for a number of debilitating diseases, clinicians and patients alike still have some questions," said an author. "Using a detailed background on the clinical development of the first EMA approved biosimilar monoclonal antibody, this article creates a useful framework for consideration of these new drug options."

Read the whole article on

More from